Evidence Snapshot
Regulatory Context
Not an FDA-approved drug; investigational CNTF-derived neurotrophic peptide mimetic studied only in animal and cell models. No adequate human therapeutic efficacy program identified.
Research Takeaway
P021 is a CNTF-derived neurotrophic peptide mimetic that already incorporates an adamantane-related structural modification in the peer-reviewed literature; commercial products sold as "P21" or "P21-adamantane" have not been independently confirmed to be chemically identical to this entity.
Evidence boundary: This does not establish that any specific commercial P21/P21-adamantane product is the same molecule studied in the cited literature.
See all 4 evidence claims →Quick Summary
P021 is a CNTF (ciliary neurotrophic factor)-derived small-molecule peptide mimetic that incorporates an adamantane-related structural modification. Peer-reviewed mouse and cell studies report effects on neurogenesis, synaptic and dendritic structure, tau and amyloid-beta pathology, and cognitive/memory measures in Alzheimer's-disease and CDKL5-deficiency models. These findings do not establish Alzheimer's prevention or treatment in humans, and a 2024 CDKL5-model study found P021 improved cellular measures but failed to raise BDNF or improve neuroanatomical defects in vivo -- illustrating limited translation from favorable cell-level effects to whole-animal outcomes. Commercially sold "P21" or "P21-adamantane" products have not been independently confirmed to be chemically identical to this peer-reviewed entity; this page treats the peer-reviewed P021 literature as describing this specific CNTF-mimetic molecule and does not extend it to any unverified commercial product without further identity confirmation.
Mechanism & Research Overview
P021 is a CNTF (ciliary neurotrophic factor)-derived small-molecule peptide mimetic that incorporates an adamantane-related structural modification. Peer-reviewed mouse and cell studies report effects on neurogenesis, synaptic and dendritic structure, tau and amyloid-beta pathology, and cognitive/memory measures in Alzheimer's-disease and CDKL5-deficiency models. These findings do not establish Alzheimer's prevention or treatment in humans, and a 2024 CDKL5-model study found P021 improved cellular measures but failed to raise BDNF or improve neuroanatomical defects in vivo -- illustrating limited translation from favorable cell-level effects to whole-animal outcomes. Commercially sold "P21" or "P21-adamantane" products have not been independently confirmed to be chemically identical to this peer-reviewed entity; this page treats the peer-reviewed P021 literature as describing this specific CNTF-mimetic molecule and does not extend it to any unverified commercial product without further identity confirmation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
P021 is a CNTF-derived neurotrophic peptide mimetic that already incorporates an adamantane-related structural modification in the peer-reviewed literature; commercial products sold as "P21" or "P21-adamantane" have not been independently confirmed to be chemically identical to this entity.
Does not establish
Evidence boundary: This does not establish that any specific commercial P21/P21-adamantane product is the same molecule studied in the cited literature.
Supported
In 3xTg-AD and related mouse models, chronic P021 administration was reported to rescue dendritic and synaptic deficits, boost neurogenesis, reduce tau and amyloid-beta pathology, and improve memory/cognitive measures.
Does not establish
Evidence boundary: Mouse-model findings do not establish Alzheimer's disease prevention or treatment efficacy in humans.
Supported
A 2024 study in a CDKL5-deficiency-disorder cell/mouse model found P021 restored neuronal proliferation and survival in vitro but failed to increase BDNF levels or improve neuroanatomical defects in vivo, yielding only limited behavioral benefit.
Does not establish
Evidence boundary: Demonstrates that favorable in-vitro cellular effects do not reliably predict in-vivo therapeutic benefit for this compound -- a direct precedent against assuming Alzheimer's-model cell/mouse findings will translate to human benefit either.
Supported
No adequate human therapeutic efficacy or safety program for P021 has been identified.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Research Areas Being Studied
Research areas discussed on this page reflect the Cognitive / Neuro category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
No Sources Listed Yet
Human, preclinical, regulatory, and review sources will appear here as they are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated .
Follow research updates for P021
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.